A stereoselective synthesis of polyhydroxylated cyclopentane β-amino acids from hexoses is reported. The reaction sequence comprises, as key steps, ring-closing metathesis of a polysubstituted diene intermediate followed by the stereoselective aza-Michael functionalization of the resulting cyclopent-1-ene-1-carboxylic acid ester. Examples of synthesis of polysubstituted 2-aminocyclopentanecarboxylic acid derivatives starting from protected d-mannose and d-galactose are presented. A general protocol for the incorporation of these highly functionalized alicyclic β-amino acids into peptides is also reported.
Recent advances in biotransformation, extraction and green production of D–mannose
D-mannose is a natural and biologically active monosaccharide. It is the C-2 epimer of glucose and a component of a variety of polysaccharides in plants. In addition, D-mannose also naturally exists in some cells of the human body and participates in the immune regulation of cells as a prebiotic. Its good physiological benefits to human health and wide application in the food and pharmaceutical industries have attracted widespread attention. Therefore, in-depth research on preparation methods of D-mannose has been widely developed. This article summarizes the main production methods of D-mannose in recent years, especially the in-depth excavation from biomass raw materials such as coffee grounds, konjac flour, acai berry, etc., to provide new ideas for the green manufacture of D-mannose.
Effect of D–mannose on Philadelphia chromosome-positive leukemia cells
Background: Although Abelson (ABL) tyrosine kinase inhibitors (TKIs) have demonstrated potency against chronic myeloid leukemia (CML), resistance to ABL TKIs can develop in CML patients after discontinuation of therapy.
Objective: Glucose metabolism may be altered in CML cells because glucose is a key metabolite used by tumor cells. We investigated whether D-mannose treatment induced metabolic changes in CML cells and reduced CML growth in the presence of ABL TKIs.
Methods: We investigated whether D-mannose treatment induced metabolic changes in CML cells and reduced CML growth in the presence of ABL TKIs.
Results: Treatment with D-mannose for 72 h inhibited the growth of K562 cells. Combined treatment using ABL TKIs and D-mannose induced a significantly higher level of cytotoxicity in Philadelphia chromosome (Ph)-positive leukemia cells than in control cells. In the mouse model, severe toxicity was observed as evidenced by body weight loss in the ponatinib and D-mannose combination treatment groups.
Conclusion: Our results indicate that metabolic reprogramming may be a useful strategy against Ph-positive leukemia cells. However, caution should be exercised during clinical applications.
Keywords: ABL tyrosine kinase inhibitor; Chronic myeloid leukemia; D-mannose; glycolysis.
The correlation between amylin and insulin by treatment with 2-deoxy-D-glucose and/or mannose in rat insulinoma ins-1E cells
Amylin or islet amyloid polypeptide (IAPP) is a peptide synthesized and secreted with insulin by the pancreatic β-cells. A role for amylin in the pathogenesis of type 2 diabetes (T2D) by causing insulin resistance or inhibiting insulin synthesis and secretion has been suggested by in vitro and in vivo studies. These studies are consistent with the effect of endogenous amylin on pancreatic βcells to modulate and/or restrain insulin secretion. Here, we reported the correlation between amylin and insulin in rat insulinoma INS-1E cells by treating 2-deoxy-D-glucose (2-DG) and/or mannose. Cell viability was not affected by 24 h treatment with 2-DG and/or mannose, but it was significantly decreased by 48 h treatment with 5 and 10 mM 2-DG. in the 24 h treatment, the synthesis of insulin in the cells and the secretion of insulin into the media showed a significant inverse association. in the 48-h treatment, amylin synthesis vs. the secretion and insulin synthesis vs. the secretion showed a significant inverse relation. The synthesis of amylin vs. insulin and the secretion of amylin vs. insulin showed a significant inverse relationship.
The p-ERK, antioxidant enzymes (Cu/Zn-superoxide dismutase (SOD), Mn-SOD, and catalase), and endoplasmic reticulum (ER) stress markers (cleaved caspase-12, CHOP, p-SAPK/JNK, and BiP/GRP78) were significantly increased or decreased by the 24 h and 48 h treatments. These data suggest the relative correlation to the synthesis of amylin by cells vs. the secretion into the media, the synthesis of amylin vs. insulin, and the secretion of amylin vs. insulin under 2-DG and/or mannose in rat insulinoma INS-1E cells. Therefore, these results can provide primary data for the hypothesis that the amylin-insulin relationships may be involved with the human amylin toxicity in pancreatic beta cells.
D–Mannose Slows Glioma Growth by Modulating Myeloperoxidase Activity
Host immune response in the tumor microenvironment plays key roles in tumorigenesis. We hypothesized that D-mannose, a simple sugar with anti-inflammatory properties, could decrease oxidative stress and slow glioma progression. Using a glioma stem cell model in immunocompetent mice, we induced gliomas in the brain and tracked MPO activity in vivo with and without D-mannose treatment. As expected, we found that D-mannose treatment decreased the number of MPO+ cells and slowed glioma progression compared to PBS-treated control animals with gliomas. Unexpectedly, instead of decreasing MPO activity, D-mannose increased MPO activity in vivo, revealing that D-mannose boosted the MPO activity per MPO+ cell. On the other hand, D-glucose had no effect on MPO activity. To better understand this effect, we examined the effect of D-mannose on bone marrow-derived myeloid cells.
We found that D-mannose modulated MPO activity via two mechanisms: directly via N-glycosylation of MPO, which boosted the MPO activity of each molecule, and indirectly by increasing H2O2 production, the main substrate for MPO. This increased host immune response acted to reduce tumor size, suggesting that increasing MPO activity such as through D-mannose administration may be a potential new therapeutic direction for glioma treatment.
Characterization of the low energy conformations and differential reactivities of D-glucose and D–mannose based oxepines
Carbohydrate-based oxepines are valuable intermediates for the synthesis of septanose carbohydrates. Here we report the characterization of the preferred conformations of D-glucose and D-mannose based oxepines 1 and 2 using computational chemistry and NMR spectroscopy. Monte Carlo conformational searches on 1 and 2 were performed, followed by DFT optimization and single-point energy calculations on the low energy conformations of each oxepine. Coupling constants were computed for all unique conformations at a B3LYP/6-31G(d,p)u+1s level of theory and weighted based on a Boltzmann distribution. These values were then compared to the experimental values collected using 3JH,H values collected from 1H NMR spectra. Information from the MC/DFT approach was then used in a least squares method that correlated DFT calculated and observed 3JH, H coupling constants.
The conformations of 1 and 2 are largely governed by a combination of the rigidifying enol ether element in combination with the reduction of unfavorable interactions. The vinylogous anomeric effect (VAE) emerged as a consequence, rather than a driver of conformations. Oxepine 1 showed greater reactivity in Ferrier rearrangement reactions relative to oxepine 2, in line with its greater %VAE.
ral D–mannose treatment suppresses experimental autoimmune encephalomyelitis via induction of regulatory T cells
D-mannose (D-m) is a glucose epimer found in natural products, especially fruits. In mouse models of diabetes and airway inflammation, D-m supplementation via drinking water attenuated pathology by modifying cellular energy metabolism, leading to the activation of latent transforming growth factor beta (TGF-β), which in turn induced T regulatory cells (Tregs). Given that Tregs are important in controlling neuroinflammation in experimental autoimmune encephalomyelitis (EAE) and likely in multiple sclerosis (MS), we hypothesized that D-m could also suppress EAE.
D-(+)-Mannosefrom Abbexa |
|
20-abx183971 |
[
100 g:
427.20 EUR ]
[
25 g:
276.00 EUR ]
[
500 g:
1111.20 EUR ]
|
D-(+)-Mannosefrom Glentham Life Sciences |
|
GC7397-100G |
100 g: 112.80 EUR |
D-(+)-Mannosefrom Glentham Life Sciences |
|
GC7397-250G |
250 g: 189.60 EUR |
D-(+)-Mannosefrom Glentham Life Sciences |
|
GC7397-25G |
25 g: 64.80 EUR |
D-(+)-Mannosefrom Glentham Life Sciences |
|
GC7397-500G |
500 g: 313.20 EUR |
D-(+)-Mannosefrom Glentham Life Sciences |
|
GC7397-100 |
100: 63.30 EUR |
D-(+)-Mannosefrom Glentham Life Sciences |
|
GC7397-25 |
25: 23.80 EUR |
D-(+)-Mannosefrom Glentham Life Sciences |
|
GC7397-250 |
250: 126.50 EUR |
D-(+)-Mannosefrom Glentham Life Sciences |
|
GC7397-500 |
500: 229.30 EUR |
D-(+)-Mannose, 99%, from woodfrom Glentham Life Sciences |
|
GC8181-500G |
500 g: 438.00 EUR |
D-(+)-Mannose, 99%, from woodfrom Glentham Life Sciences |
|
GC8181-500 |
500: 332.20 EUR |
L-(-)-Mannosefrom Glentham Life Sciences |
|
GC8426-1G |
1 g: 122.40 EUR |
L-(-)-Mannosefrom Glentham Life Sciences |
|
GC8426-250MG |
250 mg: 64.80 EUR |
L-(-)-Mannosefrom Glentham Life Sciences |
|
GC8426-500MG |
500 mg: 84.00 EUR |
L-(-)-Mannosefrom Glentham Life Sciences |
|
GC8426-5G |
5 g: 370.80 EUR |
L-(-)-Mannosefrom Glentham Life Sciences |
|
GC8426-1 |
1: 91.70 EUR |
L-(-)-Mannosefrom Glentham Life Sciences |
|
GC8426-5 |
5: 419.10 EUR |
L-(-)-Mannosefrom Glentham Life Sciences |
|
GC8426-500 |
500: 53.80 EUR |
Mannose triflatefrom Glentham Life Sciences |
|
GC1530-100MG |
100 mg: 108.00 EUR |
Mannose triflatefrom Glentham Life Sciences |
|
GC1530-1G |
1 g: 457.20 EUR |
Mannose triflatefrom Glentham Life Sciences |
|
GC1530-1 |
1: 348.10 EUR |
Mannose triflatefrom Glentham Life Sciences |
|
GC1530-100 |
100: 59.30 EUR |
Mannose Receptor (CD206)from EnoGene |
|
E8ET1702-04 |
100ul: 275.00 EUR |
Mannose (MN) ELISA Kitfrom Abbexa |
|
abx517746-96tests |
96 tests: 801.60 EUR |
Pig Mannose ELISA kitfrom BlueGene |
|
E07M0333-192T |
192 tests: 1524.00 EUR |
We found that D-m delayed disease onset and reduced disease severity in two models of EAE. Importantly, D-m treatment prevented relapses in a relapsing-remitting model of EAE, which mimics the most common clinical manifestation of MS. EAE suppression was accompanied by increased frequency of CD4+FoxP3+ Tregs in the central nervous system, suggesting that EAE suppression resulted from Treg cell induction by D-m. These findings suggest that D-m has the potential to be a safe and low-cost complementary therapy for MS.